Titre :

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30(+) Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

Auteur(s) :

Perrot, Aurore [Auteur]
Monjanel, Helene [Auteur]
Bouabdallah, Reda [Auteur]
Quittet, Philippe [Auteur]
Sarkozy, Clementine [Auteur]
Bernard, Marc [Auteur]
Stamatoullas-Bastard, Aspasia [Auteur]
Borel, Cecile [Auteur]
Bouabdallah, Krimo [Auteur]
Nicolas-Virelizier, Emmanuelle [Auteur]
Fournier, Marion [Auteur]
Morschhauser, Franck [Auteur]
Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 [GRITA]
Brice, Pauline [Auteur]

Titre de la revue :

Haematologica

Nom court de la revue :

Haematologica

Numéro :

101

Pagination :

466-473

Date de publication :

2016

Discipline(s) HAL :

Sciences du Vivant [q-bio]

Résumé en anglais : [en]

Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with ...
Lire la suite >Brentuximab vedotin was reported to be effective and safe against refractory/relapsed Hodgkin lymphoma in cohorts of between 12 to 102 patients. Herein we report our retrospective analysis of the French experience with brentuximab vedotin used alone to treat 240 refractory/relapsed Hodgkin lymphoma patients enrolled in a named patient program between 2011 and 2013. All patients had histologically documented CD30+ Hodgkin lymphoma; 74% had refractory disease or early relapses. After a median of 3 lines of chemotherapy, brentuximab vedotin was infused intravenously (1.8 mg/kg every 3 weeks). The primary endpoint was best response. Response at the end of treatment, its duration, survival data and toxicity profile were secondary endpoints. Patients received a median of 6 cycles; 68 underwent a consolidation thereafter. The best response was observed after a median of 4 cycles in 145 (60.4%) patients: 33.8% complete response/unconfirmed complete response, 26.7% partial response. Objective responses were observed as decreased (39.3%) in the 28 patients >60 years. The median response duration was 8.4 months. With median follow-up at 16.1 months, median progression-free survival was 6.8 months and this was significantly longer for patients transplanted after brentuximab vedotin (a median of 18,8 months); median overall survival was not reached. No death has been linked to brentuximab vedotin toxicity. The most common adverse events were peripheral sensory neuropathy (29.3%) and hematological toxicity. The results of this analysis support the previously reported brentuximab vedotin efficacy with manageable toxicity. Because of the short-term responses in most patients, a high-dose therapy with stem cell transplantation for responders should be considered as quickly as possible.Lire moins >

Langue :

Anglais

Audience :

Internationale

Vulgarisation :

Non

Établissement(s) :

Université de Lille
CHU Lille

Collections :

• Groupe de Recherche sur les formes Injectables et les Technologies Associées (GRITA) - ULR 7365

Équipe(s) de recherche :

Innovation/évaluation des médicaments injectables

Date de dépôt :

2019-02-26T17:07:27Z